The emerging normal and disease-related roles of anaplastic lymphoma kinase

被引:99
作者
Pulford, K
Lamant, L
Espinos, E
Jiang, Q
Xue, L
Turturro, F
Delsol, G
Morris, S
机构
[1] John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Leukaemia Res Fund Immunodiagnost Unit, Oxford OX3 9DU, England
[2] Ctr Physiopathol Toulouse Purpan, INSERM, U563, Dept Oncogenesis & Signalling Hematopoiet Cells, Toulouse, France
[3] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA
[4] St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA
[5] LSU, Hlth Sci Ctr, Feist Weiller Canc Ctr, Dept Med, Shreveport, LA USA
关键词
ALK; NPM-ALK; ALCL; IMT; lymphoma; receptor tyrosine kinase;
D O I
10.1007/s00018-004-4275-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase, the normal role of which remains to be completely elucidated. Although work carried out in mammals suggests a function in neural development, results from studies in Drosophila indicate an additional role in visceral muscle differentiation. The aberrant expression of full-length ALK receptor proteins has been reported in neuroblastomas and glioblastomas, while the occurrence of ALK fusion proteins in anaplastic large cell lymphoma (ALCL) has resulted in the identification of the new tumor entity, ALK-positive ALCL. ALK represents one of few examples of a receptor tyrosine kinase implicated in oncogenesis in both haematopoietic and non-haematopoietic tumors, given that ALK fusions also occur in the mesenchymal tumor known as inflammatory myofibroblastic tumor (IMT). The study of ALK fusion proteins, besides demonstrating their importance in tumor development, has also raised the possibility of new therapeutic treatments for patients with ALK-positive malignancies.
引用
收藏
页码:2939 / 2953
页数:15
相关论文
共 151 条
[51]  
Hernández L, 1999, BLOOD, V94, P3265
[52]   Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas -: Identification of a new TFG-ALKXL chimeric gene with transforming activity [J].
Hernández, L ;
Beà, S ;
Bellosillo, B ;
Pinyol, M ;
Falini, B ;
Carbone, A ;
Ott, G ;
Rosenwald, A ;
Fernández, A ;
Pulford, K ;
Mason, D ;
Morris, SW ;
Santos, E ;
Campo, E .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (04) :1487-1494
[53]  
Ho L, 2001, CLIN CANCER RES, V7, P2031
[54]   Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance? [J].
Hoser, G ;
Majsterek, I ;
Romana, DL ;
Slupianek, A ;
Blasiak, J ;
Skorski, T .
LEUKEMIA RESEARCH, 2003, 27 (03) :267-273
[55]   Hammerhead ribozyme-mediated cleavage of the fusion transcript NPM-ALK associated with anaplastic large-cell lymphoma [J].
Hübinger, G ;
Wehnes, E ;
Xue, L ;
Morris, SW ;
Maurer, U .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (03) :226-233
[56]   The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation [J].
Hübinger, G ;
Scheffrahn, I ;
Müller, E ;
Bai, R ;
Duyster, J ;
Morris, SW ;
Schrezenmeier, H ;
Bergmann, L .
EXPERIMENTAL HEMATOLOGY, 1999, 27 (12) :1796-1805
[57]   The tip of the coiled-coil rod determines the filament formation of smooth muscle and nonmuscle myosin [J].
Ikebe, M ;
Komatsu, S ;
Woodhead, JL ;
Mabuchi, K ;
Ikebe, R ;
Saito, J ;
Craig, R ;
Higashihara, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (32) :30293-30300
[58]   Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system [J].
Iwahara, T ;
Fujimoto, J ;
Wen, DZ ;
Cupples, R ;
Bucay, N ;
Arakawa, T ;
Mori, S ;
Ratzkin, B ;
Yamamoto, T .
ONCOGENE, 1997, 14 (04) :439-449
[59]  
Jones D, 2000, BLOOD, V96, P685
[60]  
Khoury JD, 2003, CLIN CANCER RES, V9, P3692